Oncolys BioPharma, Inc. (JP:4588)
:4588
Want to see JP:4588 full AI Analyst Report?
4588 Stock Chart & Stats
¥953.00
-¥1.00(-0.20%)
At close: 4:00 PM EST
¥953.00
-¥1.00(-0.20%)
Day’s Range― - ―
52-Week Range¥515.00 - ¥3,415.00
Previous CloseN/A
Volume332.10K
Average Volume (3M)1.52M
Market Cap
¥85.46B
Enterprise Value¥72.31B
Total Cash (Recent Filing)¥1.39B
Total Debt (Recent Filing)¥366.79M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.37
Shares Outstanding29,302,700
10 Day Avg. Volume2,742,450
30 Day Avg. Volume1,517,566
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageImproved debt-to-equity (~0.12) indicates relatively low financial leverage versus peers, giving the company structural flexibility to raise capital or absorb shocks while advancing clinical programs. Lower leverage reduces short-term default risk and preserves strategic optionality amid losses.
Expanded Balance Sheet / Funding CapacityMeaningful growth in equity and assets suggests recent capital support or reserves that extend runway for R&D. A larger balance sheet provides capacity to fund clinical development and partnerships without immediate liquidity pressure, supporting progress across multi-year programs.
Specialized R&D Focus And Novel ModalitiesA concentrated strategy on oncolytic viruses and novel therapeutic modalities represents a durable competitive niche with high scientific barriers to entry. Successful clinical advances could translate into differentiated products and long-term commercial moats if trials prove positive and IP is secured.
Bears Say
Collapsed Revenue TrendDramatic multi-year revenue decline erodes the business base and shows failure to scale commercial activities. Structurally low revenue relative to fixed R&D and SG&A means the company cannot self-fund growth, making sustained development dependent on external financing or transformational revenue inflection.
Persistent Heavy Cash BurnConsistent, large negative operating cash flows indicate the business is not generating internal funding and will likely need recurring capital raises. This persistent burn increases dilution risk, compresses management flexibility, and can force program prioritization or delays if markets tighten.
Large Recurring Operating LossesSustained multi-year operating and net losses produce negative returns on equity and gradually erode shareholder capital absent a path to profitability. Structural unprofitability limits reinvestment capacity and heightens dependence on external financiers, constraining long-term strategic options.
Oncolys BioPharma, Inc. News
4588 FAQ
What was Oncolys BioPharma, Inc.’s price range in the past 12 months?
Oncolys BioPharma, Inc. lowest stock price was ¥515.00 and its highest was ¥3415.00 in the past 12 months.
What is Oncolys BioPharma, Inc.’s market cap?
Oncolys BioPharma, Inc.’s market cap is ¥85.46B.
When is Oncolys BioPharma, Inc.’s upcoming earnings report date?
Oncolys BioPharma, Inc.’s upcoming earnings report date is May 08, 2026 which is in 14 days.
How were Oncolys BioPharma, Inc.’s earnings last quarter?
Oncolys BioPharma, Inc. released its earnings results on Feb 06, 2026. The company reported -¥15.37 earnings per share for the quarter, missing the consensus estimate of N/A by -¥15.37.
Is Oncolys BioPharma, Inc. overvalued?
According to Wall Street analysts Oncolys BioPharma, Inc.’s price is currently Overvalued.
Does Oncolys BioPharma, Inc. pay dividends?
Oncolys BioPharma, Inc. does not currently pay dividends.
What is Oncolys BioPharma, Inc.’s EPS estimate?
Oncolys BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolys BioPharma, Inc. have?
Oncolys BioPharma, Inc. has 29,302,700 shares outstanding.
What happened to Oncolys BioPharma, Inc.’s price movement after its last earnings report?
Oncolys BioPharma, Inc. reported an EPS of -¥15.37 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.343%.
Which hedge fund is a major shareholder of Oncolys BioPharma, Inc.?
Currently, no hedge funds are holding shares in JP:4588
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncolys BioPharma, Inc.
Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs and inspection services. It has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
Technical Analysis
Peptidream
―
OncoTherapy Science
―
CanBas Co., Ltd.
―
Chiome Bioscience Inc.
―
Takara Bio Inc.
―
Options Prices
Currently, No data available
---